HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

NCT04486651 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

560

Enrollment

INDUSTRY

Sponsor class

Conditions

Stomach Cancer

Interventions

DRUG: Irinotecan Hydrochloride Injection
DRUG: HX008
DRUG: Placebo

Sponsor

Taizhou Hanzhong biomedical co. LTD